PMID- 9116716
OWN - NLM
STAT- MEDLINE
DCOM- 19970421
LR  - 20201214
IS  - 0961-2033 (Print)
IS  - 0961-2033 (Linking)
VI  - 6
IP  - 1
DP  - 1997
TI  - Systemic lupus erythematosus: clinical expression and anti-Ro/SS--a response in 
      patients with and without lesions of subacute cutaneous lupus erythematosus.
PG  - 32-9
AB  - Patients with subacute cutaneous lupus erythematosus (SCLE) have recurrent 
      annular and/or psoriasiphorm skin lesions, with or without systemic disease. 
      OBJECTIVE: To analyse the clinical expression and the Ro/SS-A response associated 
      with SCLE in patients with systemic lupus erythematosus (SLE). METHODS: 128 
      consecutive patients with SLE were studied. Anti-Ro/SS-A antibodies were detected 
      by ELISA, (anti-60 kD Ro/SSA antibodies), immunoblotting (anti-60 kD and anti-52 
      kD Ro/SS-A antibodies) and counterimmunoelectrophoresis (CIE). RESULTS: Seventeen 
      patients (13.2%) showed SCLE lesions. Photosensitivity was more frequent in 
      patients with SCLE (82%) than in patients without these cutaneous lesions (45%) 
      (OR: 5.6). Arthritis (OR: 6.3), Raynaud's phenomenon (OR: 4.9), pleuritis (OR: 
      7.6), central nervous system disorder (OR: 6.4), renal disease (OR: 6.3), anemia 
      (OR: 7.9), hypocomplementemia (OR: 6.1) and anti-dsDNA antibodies (OR: 12.7) were 
      significantly more frequent in patients without SCLE. Anti-Ro/SS-A antibodies 
      were detected in 15 (88.2%) patients with SCLE and 62 (55.8%) patients without 
      SCLE by ELISA, in 10 (58.8%) and 34 (30.6%) patients by immunoblotting, and in 13 
      (76.4%) and 34 (30.6%) by CIE, respectively. Anti-60 kD-Ro/SS-A and anti-La 
      antibodies, but not anti-52 kD-Ro/SS-A, were significantly more frequent in 
      patients with SCLE than in patients without SCLE. CONCLUSIONS: The presence of 
      SCLE lesions in patients with SLE is associated with a more favourable prognosis. 
      The major anti-Ro/SS-A response is directed against the native 60 kD Ro/SS-A 
      protein.
FAU - Lopez-Longo, F J
AU  - Lopez-Longo FJ
AD  - Service of Rheumatology, Gregorio Maranon Hospital, Universidad Complutense of 
      Madrid, Spain.
FAU - Monteagudo, I
AU  - Monteagudo I
FAU - Gonzalez, C M
AU  - Gonzalez CM
FAU - Grau, R
AU  - Grau R
FAU - Carreno, L
AU  - Carreno L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lupus
JT  - Lupus
JID - 9204265
RN  - 0 (Autoantibodies)
RN  - 0 (Autoantigens)
RN  - 0 (RNA, Small Cytoplasmic)
RN  - 0 (RO60 protein, human)
RN  - 0 (Ribonucleoproteins)
RN  - 0 (SS-A antigen)
RN  - 0 (snRNP Core Proteins)
SB  - IM
MH  - Adult
MH  - Autoantibodies/*analysis
MH  - Autoantigens/*immunology
MH  - Autoimmunity/*immunology
MH  - Counterimmunoelectrophoresis
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Humans
MH  - Immunoblotting
MH  - Lupus Erythematosus, Cutaneous/*immunology
MH  - Lupus Erythematosus, Systemic/*immunology
MH  - *RNA, Small Cytoplasmic
MH  - Recurrence
MH  - Retrospective Studies
MH  - Ribonucleoproteins/*immunology
MH  - snRNP Core Proteins
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.1177/096120339700600105 [doi]
PST - ppublish
SO  - Lupus. 1997;6(1):32-9. doi: 10.1177/096120339700600105.